AIM:NYSEAMERICAN
AIM ImmunoTech Inc
0,52 $
arrow_downward
−0,09%(−0,00045) 1 p
0,52 $
arrow_downward
−0,59% (−0,0031)bedtimePärast tööaega
Suletud: 4. mai, 16:00:00 GMT −4 · USD
search
Kõik sümbolid
1 p
5 p
1 kuu
6 kuud
YTD
1 a
5 a
MAX
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse AIM põhistatistika genereerimine…
Ava
0,50 $
Kõrge
0,53 $
Madal
0,50 $
Turu kapit.
4,22 mln
Keskm. maht
434,72 tuh
Maht
110,97 tuh
52 näd kõrgeim
20,33 $
52 näd madalaim
0,48 $
Aktsiatulu
−8,62 $
Beeta
1,24
Käibivad aktsiad
8,15 mln
Töötajate arv
20
Uudised
Erinevatest veebiallikatest
investingLive
·
44 minuti eest
S&P 500 target of 7,600 reaffirmed as Goldman warns on inflation and rate cut constraints
Investor's Business Daily
·
53 minuti eest
Dow Jones Futures: Iran Attacks Spark Stock Market Losses; Palantir Slides On Earnings
Stock Titan
·
1 tunni eest
New Absci hire gets option to buy 276,200 shares at $4.92
PR Newswire
·
3 tunni eest
Cambium Networks Pursues Appeal of Nasdaq Delisting
Profiil
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
Teave üksuse AIM ImmunoTech Inc kohta
Tegevjuht-
Töötajad20
Asutatud1966
PeakontoridPhiladelphia, Pennsylvania, Ameerika Ühendriigid
Sektor-
Veebisaitaimimmuno.com
AI genereeritud sisu võib sisaldada vigu. Lisateave